Article Text

other Versions

PDF
Extended report
Etanercept normalises left ventricular mass in patients with rheumatoid arthritis
  1. Claire Immediato Daïen1,2,
  2. Pierre Fesler3,
  3. Guilhem du Cailar3,
  4. Vincent Daïen4,
  5. Thibault Mura5,6,
  6. Anne-Marie Dupuy6,
  7. Jean-Paul Cristol7,
  8. Jean Ribstein3,
  9. Bernard Combe1,2,
  10. Jacques Morel1,2
  1. 1Department of Rheumatology, University Montpellier I, Lapeyronie Hospital, Montpellier, France
  2. 2TNFα Laboratory, CNRS, Montpellier, France
  3. 3Department of Internal Medicine and Hypertension, Lapeyronie Hospital, Montpellier, France
  4. 4Department of Ophthalmology, Gui de Chauliac Hospital, and INSERM, Montpellier, France
  5. 5Department of Medical Information, Clinical Investigation Center, Gui de Chauliac Hospital, Montpellier, France
  6. 6INSERM, CIC 1001, St Eloi Hospital, Montpellier, France
  7. 7Department of Biochemistry, Lapeyronie Hospital, Montpellier, France
  1. Correspondence to Dr Jacques Morel, Département de Rhumatologie CHU-Lapeyronie, 371 Avenue du doyen Gaston Giraud, 34295 Montpellier Cedex 5, France; j-morel{at}chu-montpellier.fr

Abstract

Background Cardiovascular mortality is increased in patients with rheumatoid arthritis (RA). RA is associated with an increased left ventricular mass index (LVMI), a strong marker of cardiovascular mortality, and vessel abnormalities. Experimental studies have suggested that tumour necrosis factor α (TNFα) may induce LV hypertrophy.

Objective To study the effect of medium-term (3- and 6-months) treatment with the TNFα inhibitor etanercept (ETN) and synthetic disease-modifying antirheumatic drugs (sDMARDs) on LV morphological features and arterial stiffness in patients with RA.

Methods Consecutive female patients with active RA requiring treatment with ETN (n=28) or sDMARDs (n=20) were included. Clinical and biological monitoring, echocardiography and pulse wave velocity (PWV) assessment were performed at inclusion and at 3 and 6 months after the start of treatment. Paired t tests and multivariate linear regression analysis were used.

Results Mean LVMI tended to be higher at baseline in the ETN group than in the sDMARD group (96.5±19.8 vs 84.3±26.8 g/m2; p=0.11 for the ETN and sDMARD groups, respectively). In patients with ETN treatment, mean LVMI was significantly decreased at 3 and 6 months (−6.3±7.6 and −14.2±9.3 g/m2; p<0.001), with no change from baseline for patients with sDMARD treatment (−2.2±10.9 and −2.7±10.2 g/m2, respectively). Blood pressure (BP) and aortic PWV were not changed by either treatment.

Conclusions ETN induced a significant decrease in LVMI with medium-term treatment with no change in BP or PWV. TNFα may be an important factor of LV hypertrophy, which may explain the benefit of TNF inhibitors on cardiovascular morbidity and mortality in RA. These results need to be confirmed by larger studies and with other TNF inhibitors.

  • Anti-TNF
  • Cardiovascular Disease
  • Rheumatoid Arthritis

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.